Dr. Brendan David Curti, MD

Dr. Curti practices at Providence Portland Medical Center in Portland, Oregon, part of Providence Health & Services.

Dr. Curti's NPI, 1861494650, was assigned on August 11, 2005. Dr. Curti graduated from Georgetown University School of Medicine in 1985. Dr. Curti holds Oregon license MD23816.

Dr. Curti's primary practice is Providence Portland Medical Center, at 4805 NE Glisan Street, Portland, OR 97213 in Multnomah County. The practice phone is (503) 215-1111.

Dr. Curti's primary practice is Providence Portland Medical Center in Portland, Oregon, part of Providence Health & Services. Dr. Curti is also affiliated with OHSU Hospital. The medical group on file is Providence Medical Group, Oregon. Dmand AI also links Dr. Curti to 1 more hospital and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Curti practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Curti's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Curti is licensed in Oregon.

CMS data shows 215 Medicare services from Dr. Curti across 4 procedure codes in 2024, for 65 Medicare patients. Medicare paid $10,365 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 65 Medicare patients who saw Dr. Curti in 2024. The largest group is 65 to 74, with 34 patients. 74% of them have cancer, and 63% have high blood pressure. Their average risk score is 2.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Curti's median patient age at 75, with 23% women.

In 2024, Dr. Curti wrote 243 Medicare Part D claims for 48 patients. 53% of them were for generic drugs. CMS names the drug for 143 of them, across 5 drugs with 11 or more claims each, at $1,356,134 in total drug cost. In 2023, CMS named 145 claims across 7 drugs.

Dr. Curti accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Curti as offering telehealth.

Dmand AI links 65 papers to Dr. Curti, published from 2012 to 2024. 2015 was the busiest year, with 6. The most frequent topics are Melanoma, Antibodies, Monoclonal and Antineoplastic Combined Chemotherapy Protocols. Dr. Curti has published most often in J Immunother Cancer. Dr. Curti's most frequent co-authors are Walter John Urba, MD, PhD, Marka Rae Crittenden, MD, PhD and Joseph I. Clark, MD.

Dmand AI links Dr. Curti to 10 clinical trials, 5 of them phase 2 studies. 7 are still active or recruiting. Conditions studied include Triple Negative Breast Neoplasms, Breast Neoplasms and Breast Neoplasms, Male. Providence Health & Services sponsors the most, 5.

CMS Open Payments shows 85 general payments to Dr. Curti from 10 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 66% of the total. Merck Sharp & Dohme Corporation paid the most, $30,700.

Dr. Curti graduated from Georgetown University School of Medicine in 1985.